A study to investigate the coadministration of PTI-801, PTI-808 and PTI-428 in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 14 Mar 2018
At a glance
- Drugs PTI 428 (Primary) ; PTI 808 (Primary) ; PTI-801 Proteostasis Therapeutics (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- 14 Mar 2018 According to a Proteostasis Therapeutics media release, based on the data from this trial, triple combination study (see profile 292094 ) protocol received endorsement and a high strategic fit score from the Therapeutics Development Network (TDN) and the Clinical Trial Network (CTN) in January 2018.
- 15 Dec 2017 New trial record
- 11 Dec 2017 Results presented in a Proteostasis Therapeutics media release.